Plasma p-tau217 biomarker
Alzheimer's pathological changes begin silently 15–20 years before the first symptoms appear. p-tau217 is one of the most sensitive blood markers for this "silent window" in current clinical validation (AUC 0.93–0.96). A single blood draw — no PET scan, no lumbar puncture — can assess whether early amyloid-driven tau pathology is already present in the brain, giving you the most meaningful opportunity to act before cognitive decline begins.
Section 01
What is this test for?
Section 02
Why is this number worth trusting?
p-tau217 measures the pathology itself — not just a risk tendency
Unlike APOE genetic testing, which only indicates inherited risk, p-tau217 directly reflects the amyloid-β (Aβ)-driven phosphorylation of tau protein in the brain — the core mechanism of Alzheimer's pathology. This is why it is considered a disease-cause marker, not merely a risk marker.
Multiple head-to-head studies show p-tau217 outperforms p-tau181 and NfL
In studies distinguishing Alzheimer's from other neurodegenerative diseases — including frontotemporal dementia and Lewy body dementia — p-tau217 has consistently demonstrated higher diagnostic accuracy than traditional plasma markers including p-tau181 and neurofilament light chain (NfL).
※ The degree of advantage over p-tau181 may vary depending on the antibody version used
Latest fully automated testing achieves AUC 0.93–0.96
A 2024–2025 study of 1,767 patients across five centers (Nature Medicine) validated fully automated plasma p-tau217 at AUC 0.93–0.96 — closely matching CSF testing and approaching the accuracy of PET scanning, with none of the cost or invasiveness.
Highest validated accuracy for p-tau217 / Aβ42 ratio
Using the Lumipulse fully automated platform, AUC for detecting abnormal Aβ PET reached 0.963–0.966
Large-scale validation across five clinical centers
Nature Medicine 2025 study spanning five centers in both primary and secondary care settings — AUC consistently 0.93–0.96 across all cohorts
Diagnostic accuracy comparison by plasma marker (AUC)
Ref: Ashton et al. JAMA Neurology 2024; Warmenhoven et al. Brain 2025; Palmqvist et al. JAMA 2020
Section 02
Who should know — sooner rather than later?
Genetic factors significantly raise your risk. Early screening before symptoms appear offers the most meaningful window for intervention.
Standard cognitive tests can't detect early pathology. p-tau217 provides objective evidence at the stage where something feels off — but nothing shows up yet.
MCI has multiple causes — not all progress to dementia. p-tau217 helps determine whether Alzheimer's pathology is involved, supporting more informed next steps.
Alzheimer's pathology can begin as early as your 40s. Establishing a personal baseline now makes future tracking meaningful.
Section 03
By the time symptoms appear, it's already 15 years too late
"Waiting until memory loss is noticeable means missing the window that matters most."
Alzheimer's disease progresses silently over decades. Amyloid plaques and tau tangles begin accumulating 15–20 years before any noticeable cognitive decline — a period that medicine now recognizes as the most critical window for intervention.
Until recently, detecting pathology during this window required expensive PET scans or invasive lumbar punctures. p-tau217 blood testing changes that — the same level of clinical precision, from a single blood draw.
⚠ This test provides blood biomarker assessment for personal health management purposes only. Results do not constitute a clinical diagnosis. Please consult a neurologist if you have concerns.
Alzheimer's pathological changes (amyloid accumulation) precede clinical symptoms by 15–20 years
Jack et al. / Lancet Neurology 2013
p-tau217's clinically validated accuracy in distinguishing Alzheimer's from non-Alzheimer's dementia — outperforming traditional blood markers
Hansson et al. / JAMA 2020
Projected dementia cases in Taiwan by 2041 — 1 in 10 adults over 65, with Alzheimer's accounting for 60–70% of all cases
Taiwan Alzheimer Disease Association / 2023
Section 04
Have you thought this too?
Dementia is not an inevitable consequence of aging. It results from accumulated brain pathology. Early detection creates time for lifestyle intervention, treatment evaluation, and family planning — while options still exist.
✓Early detection opens the window where action is most meaningful
Routine health checks cannot detect early neurodegeneration. p-tau217 is designed precisely for the pre-symptomatic stage — assessing risk before cognitive decline becomes noticeable, not after.
✓p-tau217 detects pathology 15–20 years before symptoms appear
Knowing early means more options: lifestyle changes (sleep, exercise, diet), cognitive training, clinical trial eligibility, and — most importantly — making personal and financial decisions while cognitive function is still intact.
✓Knowing your risk lets you prepare while you still can
p-tau217 has demonstrated AUC 0.92–0.97 in multiple large-scale studies — closely matching CSF testing and achieving comparable accuracy to PET scans, at a fraction of the cost and with no radiation or invasive procedure.
✓AUC 0.96 — accuracy on par with PET scanning
Alzheimer's pathology can begin accumulating in your 40s. Those with family history, chronic stress, poor sleep, or metabolic issues should consider establishing a baseline early — so future changes have something to be measured against.
✓Ages 40–50 is the ideal time to establish your baseline
An elevated p-tau217 reflects signs of pathological activity in the brain — not a diagnosis. Results must be interpreted alongside clinical evaluation, family history, and other markers by a qualified neurologist.
✓Elevated values are a signal, not a verdict — professional guidance required
Section 05
One data point, or the full picture?
p-tau217 gives you an early risk signal from the brain. Body Decode lets you see the complete picture behind neurodegeneration — hormones, metabolism, oxidative stress, immune function — so you can find where intervention is actually possible.
Single neurodegeneration marker
68 core markers + add-on tests of your choice
From NT$ 13,800
"p-tau217 is the signal. Body Decode tells you why — and what you can do about it."
Learn about Body Decode →
